Sunday 18 October 2026
Export ACIU’s income statement to Excel — free account
AC Immune
ACIU Healthcare Biotechnology
AC Immune’s revenue for fiscal 2025 (year ended December 2025) was $4.3 million, down 86.1% from fiscal 2024. In the quarter to June 2026, revenue grew 29.7%, EPS grew 9.52% and free cash flow grew 4.66%, each against the same quarter a year earlier.
2.39
0.06
−2.45%
Follow ACIU
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | 1 | 3 | 7 | 2 | — | — | — | 5 | 2 |
P/E ratio |
37.17 | 0.00 | 0.00 | 12.72 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
28.63 | 28.34 | 17.55 | 14.99 | 8.52 | — | 3.29 | 7.71 | (1.29) | (3.99) |
P/S ratio |
0.00 | 37.02 | 79.45 | 5.38 | 22.59 | — | 28.75 | 61.84 | 8.66 | 73.36 |
Altman Z″-Score (non-manufacturers) |
15.56 | 11.10 | 12.14 | 16.88 | 12.17 | — | 7.40 | 4.00 | (3.71) | (11.78) |
P/FCF ratio |
16.71 | 0.00 | 0.00 | 11.21 | 0.00 | — | 0.00 | 0.00 | 3.63 | 0.00 |
Beneish M-Score |
(1.38) | (1.65) | (3.06) | 11.17 | 1.77 | — | — | 9.12 | (6.56) | 1.01 |
P/Operating CF |
494.37 | 107.08 | (47.86) | (44.92) | (18.75) | — | (9.74) | (23.04) | 48.36 | (17.89) |
P/B ratio |
4.30 | 6.42 | 3.22 | 2.19 | 1.62 | — | 1.04 | 2.22 | 2.11 | 5.84 |
Price to Tangible BV |
4.30 | 6.42 | 3.22 | 2.19 | 1.62 | — | 1.49 | 3.24 | 3.83 | 0.00 |
EV/Sales |
0.00 | 30.90 | 53.60 | 2.81 | 8.09 | — | 9.13 | 44.36 | 2.69 | 48.34 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 6.80 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
12.15 | (28.33) | (8.75) | 5.64 | (2.10) | — | (0.76) | (4.23) | 1.12 | (2.49) |
EV/FCF |
12.52 | (26.19) | (8.39) | 5.84 | (2.04) | — | (0.75) | (4.18) | 1.13 | (2.46) |
Quick Ratio |
15.39 | 12.85 | 14.29 | 16.50 | 16.14 | 9.92 | 10.71 | 8.73 | 1.65 | 0.98 |
Current Ratio |
15.61 | 13.28 | 14.75 | 16.72 | 16.53 | 10.12 | 11.16 | 9.22 | 1.71 | 1.02 |
Net Debt/EBITDA |
14.95 | 5.65 | 3.83 | (6.29) | 3.81 | 2.59 | 1.79 | 2.00 | 3.30 | 1.37 |
Debt/Assets |
0.00% | 0.30% | 0.26% | 0.22% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.20 | 0.14 | 0.04 | 0.45 | 0.06 | 0.00 | 0.02 | 0.08 | 0.13 | 0.02 |
Operating CF/Net income |
0.80 | 0.84 | 0.87 | 1.22 | 0.96 | 0.90 | 1.04 | 1.11 | (1.29) | 0.98 |
Capex/Depreciation |
(3.23) | (3.11) | (1.93) | (1.48) | (0.83) | (1.10) | (0.53) | (0.36) | (0.27) | (0.35) |
Interest Coverage |
(40.85) | (5.56) | (166.26) | 11.30 | (332.86) | (135.98) | (199.57) | (304.75) | (393.75) | (362.98) |
| (6.59%) | (20.39%) | (34.69%) | 20.07% | (26.21%) | (33.03%) | (34.41%) | (33.94%) | (37.74%) | (93.59%) | |
| (5.96%) | (18.34%) | (31.09%) | 18.22% | (23.76%) | (29.54%) | (30.84%) | (30.32%) | (24.83%) | (37.92%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (146.26%) | (95.42%) | (58.19%) | 0.00% | 0.00% |
Return on Tangible Assets |
(4.86%) | (21.62%) | (27.82%) | 16.28% | (27.87%) | (38.88%) | (58.54%) | (47.18%) | (68.99%) | (1,753.26%) |
Average Days of Receivables |
8.13 | 16.54 | 22.07 | 1.00 | 7.78 | 0.00 | 36.36 | 380.32 | 14.76 | 99.90 |
Research and Development Expense of Revenue |
111.03% | 161.26% | 615.47% | 45.42% | 385.50% | 0.00% | 1,533.31% | 368.94% | 229.12% | 1,579.52% |
Selling, General and Administrative Expense of Revenue |
34.01% | 50.02% | 173.30% | 14.46% | 120.26% | 0.00% | 401.24% | 103.41% | 63.20% | 450.44% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.19 | 0.27 | 0.28 | 0.22 | 0.33 |
Share Based Compensation of Revenue |
5.67% | 7.80% | 35.00% | 2.55% | 26.49% | 0.00% | 84.62% | 29.49% | 20.03% | 123.03% |
Graham Net Nets |
0.23 | 0.15 | 0.30 | 0.45 | 0.60 | — | 0.63 | 0.29 | 0.23 | (0.05) |
Graham Number |
0.00 | 0.00 | 0.00 | 7.65 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
2.69% | (3.60%) | (8.89%) | 7.86% | (17.79%) | — | (40.72%) | (15.14%) | (21.11%) | (26.75%) |
Free Cash Flow Yield |
5.98% | (3.19%) | (8.04%) | 8.92% | (17.55%) | — | (42.45%) | (17.16%) | 27.54% | (26.76%) |
Revenue per Share |
0.47 | 0.36 | 0.12 | 1.58 | 0.23 | 0.00 | 0.05 | 0.19 | 0.31 | 0.04 |
Operating CF per Share |
(0.11) | (0.39) | (0.73) | 0.79 | (0.88) | (0.96) | (0.92) | (0.79) | 0.75 | (0.83) |
Capex per Share |
(0.02) | (0.03) | (0.03) | (0.03) | (0.02) | (0.04) | (0.02) | (0.01) | (0.01) | (0.01) |
Free Cash Flow per Share |
(0.13) | (0.43) | (0.76) | 0.76 | (0.91) | (1.00) | (0.94) | (0.80) | 0.74 | (0.84) |
Cash per Share |
3.08 | 2.21 | 3.08 | 4.11 | 3.35 | 2.89 | 1.54 | 1.36 | 1.89 | 1.10 |
Shareholders Equity per Share |
2.89 | 2.08 | 2.94 | 3.88 | 3.20 | 3.39 | 2.12 | 2.11 | 1.28 | 0.54 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
2.89 | 2.08 | 2.94 | 3.88 | 3.20 | 3.39 | 2.12 | 2.11 | 1.28 | 0.54 |
Free Cash Flow |
(6.65) | (24.29) | (46.96) | 53.68 | (65.23) | (74.75) | (78.39) | (68.18) | 74.14 | (84.67) |
Working Capital |
147.19 | 121.73 | 183.87 | 277.05 | 232.25 | 199.79 | 122.20 | 124.29 | 80.83 | 2.45 |
Capital Expenditures |
(0.91) | (1.83) | (1.90) | (1.90) | (1.75) | (2.88) | (1.30) | (0.89) | (0.65) | (1.07) |
Net Current Asset Value |
143.33 | 116.22 | 177.89 | 267.69 | 222.39 | 189.47 | 116.47 | 114.71 | 60.60 | (15.26) |
EV/EBIT |
0.00 | 0.00 | 0.00 | 7.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.04 | 0.09 | 0.26 | 0.02 | 0.11 | 0.00 | 0.31 | 0.05 | 0.02 | 0.25 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 13.42 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.25 | 0.25 | 0.29 | 0.33 | 0.45 | 0.47 | 0.55 | 0.66 | 0.82 | 1.26 |
Cash ROIC |
(2.22%) | (9.89%) | (12.60%) | 9.50% | (13.86%) | (15.88%) | (25.66%) | (23.21%) | 23.50% | (51.47%) |
Accounts Receivable Turnover |
58.56 | 28.24 | 10.68 | 297.72 | 50.11 | 0.00 | 9.38 | 1.87 | 3.37 | 3.54 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | — | — | 0.00 | — | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | — | — | 0.00 | — | — | — | — |
Average Receivables |
0.40 | 0.73 | 0.69 | 0.38 | 0.33 | 0.41 | 0.44 | 8.79 | 9.22 | 1.22 |
Average Payables |
2.94 | 2.60 | 1.57 | 1.08 | 1.24 | 2.26 | 1.58 | 1.42 | 2.44 | 2.76 |
Average Assets |
120.84 | 146.33 | 167.56 | 251.08 | 277.92 | 270.34 | 240.44 | 199.24 | 232.97 | 224.24 |
Average Common Equity |
109.25 | 131.65 | 150.17 | 227.91 | 252.02 | 241.82 | 215.45 | 178.01 | 153.23 | 90.85 |
Columns are period end dates